A live attenuated H7N7 candidate vaccine virus was generated by reverse genetics using the modified hemagglutinin (HA) and neuraminidase (NA) genes of highly pathogenic ( 
Highly pathogenic avian influenza (HPAI) is a disease of poultry that is caused by H5 or H7 avian influenza viruses and is associated with up to 100% mortality (2) . Influenza A H7 subtype viruses from both Eurasian and North American lineages have resulted in more than 100 cases of human infection since 2002 in the Netherlands, Italy, Canada, the United Kingdom, and the United States. These cases include outbreaks of HPAI H7N7 virus in the Netherlands in 2003 that resulted in more than 80 cases of human infection and one fatality; HPAI H7N3 virus in British Columbia, Canada, in 2004 that resulted in two cases of conjunctivitis; a cluster of human infections of low-pathogenicity avian influenza (LPAI) H7N2 virus in the United Kingdom in 2007 that resulted in several cases of influenza-like illness and conjunctivitis; and a single case of respiratory infection in New York in 2003 (3-6, 17, 27) .
Due to an unprecedented geographic spread of H5 subtype viruses since 2003 and the continued occurrence of sporadic cases of H5N1 infections in humans, much emphasis has been placed on the pandemic threat posed by H5 subtype viruses. However, H7 subtype viruses also have significant pandemic potential. Humans are immunologically naïve to the H7 avian influenza viruses (16) , and LPAI H7 subtype viruses circulating in domestic poultry and wild birds in Eurasia and North America have the potential to evolve and acquire an HP phenotype either by accumulating mutations or by recombination at the hemagglutinin (HA) cleavage site resulting in a highly cleavable HA that is a virulence motif in poultry (30, 33, 34) . Recent work also suggests that contemporary North American lineage H7 subtype viruses, isolated in 2002 to 2003, are partially adapted to recognize ␣2-6-linked sialic acids, which are the receptors preferred by human influenza viruses and are preferentially found in the human upper respiratory tract (7) . Moreover, coinfection and genetic reassortment of RNA genomes between H7 avian influenza viruses and human influenza viruses, including the seasonal H1N1 and H3N2 and pandemic H1N1 viruses, could result in the generation of reassortant viruses with the capacity to efficiently transmit among people and result in a pandemic. Domesticated birds may serve as important intermediate hosts for the transmission of wild-bird influenza viruses to humans, as may pigs, as evidenced by human infections with swine-origin 2009 pandemic H1N1 influenza virus throughout the world.
Vaccination is the most effective method for the prevention of influenza. However, technical limitations result in delays in the rapid generation and availability of a strain-specific vaccine against an emerging pandemic virus. The emergence of antigenically distinct virus clades poses a substantial challenge for the design of vaccines against H5N1 viruses because of the possible need for clade-specific vaccines (1) . Similar challenges are present for the generation of H7 subtype vaccine candidates, because antigenically distinct H7 subtype viruses, including North American lineage H7N2 and H7N3 and Eurasian lineage H7N7 and H7N3 viruses, have caused human disease.
The successful control of H7 influenza virus in poultry has been achieved by stamping out and by vaccination of poultry (9) . Vaccines for human use against both lineages of H7 influenza virus are under development, and candidate vaccines have been evaluated in preclinical and clinical studies (14, 23, 29, 42) .
We have previously analyzed the antigenic relatedness among H7 viruses from Eurasian and North American lineages using postinfection mouse and ferret sera (22) . Among 10 H7 viruses tested, A/Netherlands/219/03 (H7N7) virus induced the most broadly cross-neutralizing antibodies (Abs) (22) . Based on the phylogenetic relationships and its ability to induce broadly cross-neutralizing antibodies in mice and ferrets, we selected the A/Netherlands/219/03 (NL/03) (H7N7) virus from the Eurasian lineage for vaccine development. We used reverse genetics to generate a live attenuated cold-adapted (ca) H7N7 candidate vaccine virus bearing a modified HA, a wild-type (wt) neuraminidase (NA) gene from the NL/03 wt virus, and the six internal protein gene segments from the cold-adapted (ca) influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (AA ca) (H2N2). The immunogenicity and protective efficacy against challenge with HP and LP H7 viruses from the Eurasian and North American lineages of the reassortant H7N7 NL03/AA ca vaccine virus were evaluated in mice, ferrets, and African green monkeys (AGMs). Virus stocks for the wt viruses were propagated in the allantoic cavity of 9-to 11-day-old embryonated specific-pathogen-free (SPF) hen's eggs at 37°C. The allantoic fluid from eggs inoculated with wt viruses was harvested 24 h postinoculation and tested for hemagglutinating activity. Eggs inoculated with ca reassortant viruses were incubated at 33°C and were harvested at 3 days postinoculation. Infectious allantoic fluids were pooled, divided into aliquots, and stored at Ϫ80°C until use. The 50% tissue culture infectious dose (TCID 50 ) for each virus was determined by titration of serially diluted virus in Madin-Darby canine kidney (MDCK) cells and calculated by the method developed by Reed and Muench (32) .
MATERIALS AND METHODS

Viruses
All experiments, including animal studies with HP H7 AI viruses and the reassortant virus, were conducted by using enhanced biosafety level 3 (BSL-3) containment procedures in laboratories approved for use by the U.S. Department of Agriculture and Centers for Disease Control and Prevention. Studies with mice were conducted at the National Institutes of Health (NIH), studies with ferrets and AGMs were conducted at Bioqual, Inc. (Rockville, MD), and studies with chickens were conducted at the Southeast Poultry Research Laboratory (SEPRL). Experiments with mice, ferrets, and AGMs were approved by the National Institutes of Health Animal Care and Use Committee. Experimental studies with chickens were approved by the USDA (SEPRL) Animal Care and Use Committee.
Plasmids and transfections. cDNAs generated by reverse transcription (RT)-PCR from all six internal protein gene segments of the AA ca virus were cloned into plasmid pAD3000. This plasmid is a derivative of plasmid pHW2000 (18) that contains polymerase I (Pol I) and Pol II promoters for the expression of viral RNA (vRNA) and mRNA, respectively, from the full-length viral gene segment insert. Similarly, cDNAs derived by RT-PCR of the wt H7 HA gene, with a deletion and a point mutation of the sequence encoding 3 basic amino acids at the HA1-HA2 cleavage site, and the wt N7 NA gene from the H7N7 NL/03 virus were cloned into pAD3000. Sequences of all of the inserts were confirmed. For the H7N7 reassortant virus, the six plasmid DNAs encoding the internal protein genes of the AA ca virus were combined with the two plasmids encoding the modified H7 gene and wt N7 gene, and Vero cells were transfected with the eight-plasmid mixture by electroporation. Seed virus stocks were generated by limiting dilution in SPF eggs, followed by expansion in SPF eggs.
Phenotypic analysis of the reassortant viruses. The temperature sensitivity (ts) phenotype of the parent and reassortant viruses was assessed by evaluating the cytopathic effect (CPE) in primary chick kidney (PCK) cells at 33°C and 39°C. Viruses that displayed a Ն100-fold reduction in titer at 39°C compared with that observed at the permissive temperature (33°C) were considered ts.
The ca phenotypes of the parent and reassortant viruses were determined by comparing their infectivities in PCK cells at 25°C and 33°C. Cold-adapted viruses can replicate efficiently at low temperatures; the ca phenotype is defined as a less-than-100-fold reduction of the virus titer at 25°C compared with that at 33°C. Cells incubated at 33°C or 39°C were examined for CPE at 6 days postinfection (dpi), and cells incubated at 25°C were examined for CPE at 10 days postinfection.
Plaque assay with and without trypsin. Chicken embryo fibroblast (CEF) cells in six-well tissue culture plates were inoculated with 0.1 ml of virus serially diluted in Leibowitz (L-15) medium. The H7N7 NL/03 wt and ca viruses were adsorbed for 1 h, with shaking every 15 min. Wells were overlaid with 1.8% (wt/vol) Bacto agar (Difco) mixed 1:1 with 2ϫ medium 199 containing antibiotics and amphotericin B (Fungizone) with or without 0.1 g/ml porcine tosyl phenylalanyl chloromethyl ketone (TPCK) trypsin (Sigma). Plates were incubated at 33°C and 37°C for 4 to 5 days. Agarose overlays were carefully dislodged, and the cell monolayers were fixed with 100% methanol. Cell monolayers in each well were rinsed with 2 ml of Blotto (5% nonfat dry milk in 1ϫ phosphate-buffered saline [PBS] ) and incubated for 1 h at room temperature with 0.5 ml/well of a 1:1,000 dilution of the primary antibody in Blotto (chicken anti-AA ca antibody; MedImmune). Plates were washed three times with Blotto and incubated with 0.5 ml/well of a 1:2,000 dilution of rabbit anti-chicken IgY H&L horseradish peroxidase (HRP) (Pierce, Rockford, IL) secondary antibody in Blotto for 1 h at room temperature. Plates were washed three times with PBS, and plaques were stained by using 0.5 ml/well of 3-amino-9-ethylcarbazole (AEC) substrate solution (Dako, Carpinteria, CA) at 37°C for 30 to 45 min. Plates were washed once with water and dried at room temperature. The number of plaques in each well was counted, and titers were recorded as PFU per ml.
Pathogenicity and infectivity studies in chickens. An intravenous (i.v.) pathogenicity test (38) was used to determine the pathogenicity of the H7N7 NL/03 ca virus for chickens. Eight 4-week-old White Leghorn chickens were inoculated i.v. with the H7N7 NL/03 ca virus at a dose of 0.2 ml of a 1:10 dilution of stock virus and were monitored for mortality up to 10 dpi. To determine infectivity via a simulated natural route of exposure, a separate group of 10 chickens was inoculated intranasally (i.n.) with 10 6 TCID 50 of the H7N7 NL/03 ca virus. Oropharyngeal and cloacal swabs were collected for virus isolation at 3 dpi. Two birds from the i.n. inoculated group were euthanized at 3 dpi for virus isolation from kidney, heart, brain, and lungs. All the remaining chickens were euthanized and bled at 14 dpi, and sera were tested for evidence of seroconversion by an agar gel precipitin assay.
Pathogenicity and replication studies in mice. To determine the 50% lethal dose (LD 50 ) of the H7N7 wt and reassortant ca viruses, groups of 4-to 6-weekold female BALB/c mice were anesthetized and infected i.n. with serial 10-fold dilutions of the viruses in 50 l. Mice were monitored daily for 14 dpi for mortality.
To assess the ability of the viruses to replicate in different organs, groups of 12 female BALB/c mice were inoculated i.n. with 10 6 TCID 50 of the H7N7 NL/03 wt, H7N7 NL/03 ca, AA wt, or AA ca virus. At 2, 3, and 4 dpi, four mice from each group were euthanized, and lungs, nasal turbinates, spleen, and brains were harvested, weighed, and homogenized in L-15 medium containing antibiotics to make a 10% (wt/vol) tissue homogenate. Titers of tissue homogenates clarified by low-speed centrifugation in 24-and 96-well culture plates containing MDCK cells were determined, and titers are expressed as log 10 TCID 50 /g of tissue.
Replication in ferrets. The abilities of H7N7 ca and wt viruses to replicate in ferrets were compared. Groups of three 8-to 10-week-old ferrets (Simonsen Laboratories, CA) were prebled, tested by a hemagglutination inhibition assay, and found to be seronegative for antibodies to seasonal H3N2 and H1N1 influ-VOL. 84, 2010 LIVE ATTENUATED H7N7 VACCINE 11951 enza viruses. Each ferret was inoculated i.n. with 10 7 TCID 50 of the H7N7 NL/03 ca vaccine or the H7N7 NL/03 wt virus in a volume of 0.2 ml (0.1 ml per nostril). At 3 dpi, ferrets were euthanized, and nasal turbinates, lungs, olfactory bulbs, and brain tissue were harvested. The nasal turbinates, olfactory bulbs, and brain tissue were titrated on MDCK monolayers as described above, and titers are expressed as log 10 TCID 50 /g of tissue. The lung tissues were homogenized, serial 10-fold dilutions were prepared, and 0.1 ml was inoculated into four 9-to 11-day-old embryonated SPF hen's eggs. Eggs were incubated at 33°C for 72 h for the ca vaccine virus or 37°C for 24 h for wt virus. Allantoic fluid from each egg was subjected to a hemagglutination assay using 0.5% turkey red blood cells. Virus titers were determined as the 50% egg infectious dose (EID 50 ) per gram of tissue by using the method of Reed and Muench (32) .
Replication in African green monkeys. Adult AGMs (Chlorocebus aethiops), male and female, were used. Four AGMs were inoculated with 2 ϫ 10 6 TCID 50 of virus (1.0 ml of 1 ϫ 10 6 TCID 50 i.n. plus 1.0 ml of 1 ϫ 10 6 TCID 50 intratracheally [i.t.]); biological samples, including nasal and pharyngeal swabs, and nasal wash samples were collected daily; and tracheal lavage fluid was collected every other day. Tissue samples, including lungs, trachea, and nasal turbinates, were collected at necropsy 2 and 4 days after viral inoculation, and the virus titers were measured on MDCK cells. For sampling of lung tissue, small portions of distal and proximal sites of cranial and caudal lobes from both sides (right and left) of the lungs were harvested. The lung titer for each animal is expressed as a mean titer Ϯ the standard error (SE) for eight samples.
Evaluation of immunogenicity of the vaccine candidate in mice and ferrets. Groups of four 4-to 6-week-old female BALB/c mice were immunized i.n. with 1 or 2 doses (28 days apart) of 50 l containing 10 6 TCID 50 of the H7N7 NL/03 ca vaccine virus or L-15 medium (mock immunized), and sera were collected from these mice on 0, 28, and 56 dpi. Similarly, groups of three 8-to 10-week-old ferrets that were seronegative for antibodies to circulating H3N2 and H1N1 human influenza viruses were immunized i.n. with 1 or 2 doses (28 days apart) of 0.2 ml (0.1 ml/nostril) containing 10 7 TCID 50 of the H7N7 NL/03 ca virus or L-15 medium (mock immunized). Sera were collected at 0, 28, and 56 dpi. Neutralizing antibody titers in the postimmunization sera against the homologous and heterologous wt H7 viruses were determined in a microneutralization (MN) assay as described previously (23) . The neutralizing antibody titer was defined as the reciprocal of the highest dilution of serum that completely neutralized the infectivity of 100 TCID 50 of the virus as determined by the absence of CPE at day 4.
Evaluation of the efficacy of the vaccine candidate in mice. (i) Protection from lethality. Groups of 4-to 6-week-old female BALB/c mice were immunized i.n. with 1 dose of 10 6 TCID 50 of H7N7 NL/03 ca or L-15 medium (mock immunized). Groups of five mice were challenged at 4 weeks postimmunization with 50 l containing 30 times the LD 50 of the homologous H7N7 NL/03 wt virus, a heterologous ck/BC/04 (H7N3) wt virus from the North American lineage, and a heterologous tk/EG/63 (H7N3) wt virus from the Eurasian lineage. Mice were monitored daily for 14 days postchallenge.
(ii) Protection from replication of the challenge virus in mice. The level of pulmonary replication and extrapulmonary spread of the challenge viruses was evaluated in mice. Groups of four mice that received 1 or 2 doses of 10 6 TCID 50 of the H7N7 NL/03 ca vaccine candidate or L-15 medium (mock immunized) were challenged 4 weeks later with 10 5 TCID 50 of the homologous H7N7 NL/03 wt virus or heterologous ck/BC/04 (H7N3) wt, tk/EG/63 (H7N3) wt, or tk/Italy/99 (H7N1) wt virus from the North American and Eurasian lineages. At 2 and 4 dpi, nasal turbinates, lungs, spleen, and brains were harvested and homogenized, and the titers were determined on MDCK cells. Log-transformed viral titers were compared by using the Mann-Whitney U test.
Evaluation of the efficacy of the vaccine candidate in ferrets. The level of pulmonary replication and extrapulmonary spread of the challenge viruses in ferrets was evaluated. Groups of three 8-to 10-week-old ferrets that were seronegative for antibodies to circulating H3N2 and H1N1 human influenza viruses were immunized i.n. with 1 or 2 doses of 10 7 TCID 50 of H7N7 NL/03 ca or L-15 medium (mock immunized) in a volume of 0.2 ml/ferret (0.1 ml/nostril). Ferrets were challenged 4 weeks after dose 1 or 2 with 10 6 TCID 50 of the homologous H7N7 NL/03 wt virus and heterologous ck/BC/04 (H7N3) wt or tk/EG/63 (H7N3) wt virus from the North American and Eurasian lineages. Ferrets were euthanized 3 days postchallenge, and nasal turbinates, lungs (right and left lower lobes), and brains were harvested and homogenized. Tissue homogenates of nasal turbinates and brain tissues were titrated in MDCK cells, and virus titers were determined and expressed as log 10 TCID 50 /g of tissue. Because embryonated eggs are more sensitive for detecting low concentrations of virus, lung homogenates from the ferrets were titrated in embryonated eggs, and virus titers are expressed as EID 50 /g of tissue. Log-transformed viral titers were compared by using the Mann-Whitney U test.
Evaluation of the immunogenicity and efficacy of the vaccine in African green monkeys. AGMs were inoculated with the H7N7 NL/03 ca virus as indicated above. Sixty days after vaccination, AGMs were challenged with 2 ϫ 10 6 TCID 50 H7N7 NL/03 wt virus i.n. and i.t. Tissues were harvested at 2 days after challenge infection for virus titration as indicated above. Immune responses were assessed by measuring hemagglutination-inhibiting (HAI) and neutralizing antibodies in serum. HAI antibody titers were determined by standard methods, using 4 HA units of virus in V-bottom 96-well microtiter plates with 0.5% turkey erythrocytes. Neutralizing antibody titers were also evaluated with the MN assay, as described above.
Evaluation of the role of CD4 ؉ and CD8 ؉ T cells in vaccine-induced protection in mice. Following 1 or 2 doses of the H7N7 NL/03 ca vaccine, CD4 ϩ and/or CD8 ϩ T cells were depleted in mice as described previously (12, 15) by the intraperitoneal (i.p.) injection of 1 mg/ml of anti-CD4 Ab (clone GK 1.5) and/or 1 mg/ml of anti-CD8 Ab (clone 2.43) 3 days before and after lethal challenge with H7 wt viruses. An irrelevant Ab (SFR-DR5) was used as a negative control. Mice were observed for signs of illness and weighed daily for 14 days.
Evaluation of the role of antibody in vaccine-induced protection of mice. Postimmunization serum was generated in 50 mice that received 1 or 2 doses of the H7N7 NL/03 ca vaccine virus (10 6 TCID 50 ) i.n. on days 0 and 28. On day 56, all the vaccinated mice were exsanguinated, sera collected from these mice were pooled, and a pool of nonimmune serum from uninfected mice was used as a control. In the passive-transfer experiment, groups of five naïve mice received 1 ml of a 1:2 or 1:10 dilution of sera collected after 1 or 2 doses of the H7N7 NL/03 ca vaccine by i.p. injection a day before challenge with 10 5 TCID 50 of homologous H7N7 NL/03 wt or heterologous H7N3 ck/BC/04 wt, H7N3 tk/EG/63 wt, or H7N1 tk/Italy/99 wt virus. Mice were monitored daily for 14 days.
RESULTS
Generation of H7N7 NL/03 ca virus.
A reassortant virus containing a modified H7 HA gene, an N7 NA gene derived from the influenza A/Netherlands/219/03 (NL/03) (H7N7) wt virus, and the remaining gene segments from the AA ca virus was generated by plasmid-based reverse genetics as previously described (37) . The HA gene was modified by the removal of the sequence encoding 3 basic amino acids at the HA cleavage site (Table 1) to generate a sequence that is present in avian influenza viruses that are not highly pathogenic for poultry. The reassortant virus was isolated and biologically cloned by limiting dilution in eggs. The nucleotide sequence of each gene segment of the NL/03 ca virus was confirmed to be identical to the sequence of the corresponding gene in the parent viruses. The five loci in the AA ca virus that specify temperature sensitivity (ts) and attenuation (att) phenotypes were present in the reassortant H7N7 NL/03 ca virus (20, 21) .
In vitro phenotypes: trypsin dependence and ts. The HA gene in the H7N7 NL/03 ca virus differed from the HA gene in the corresponding NL/03 wt parent virus in the absence of the multibasic amino acid motif at the cleavage site. The presence of the multibasic amino acid sequence in the HA gene of an H7 or H5 subtype influenza A virus confers the ability to form (20, 21) , and these phenotypes were seen in H9N2, H5N1, and H7N3 reassortant ca viruses (10, 23, 37) . Consistent with previous findings, the H7N7 NL/03 ca and the parent AA ca viruses replicated equally well at 25°C and 33°C; thus, the NL/03 ca virus demonstrated the ca phenotype ( Table 2 ). The H7N7 NL/03 ca and the parent AA ca viruses were restricted in replication at 39°C (ts); in contrast, the H7N7 NL/03 wt virus replicated equally well at 33°C and 39°C (Table 2) . Thus, the H7N7 NL/03 ca virus possesses the ts phenotype. We have previously observed that the H5N1 wt virus was able to replicate efficiently at 25°C, indicating the variability of the biology of influenza viruses in nature (37) , and in this experiment, the AA wt virus also possesses the ca phenotype (Table 2) .
Attenuation in vivo in chickens, mice, ferrets, and African green monkeys. (i) Level of attenuation in chickens following i.v. and i.n. administration. Clinical signs of illness were not observed in chickens upon i.n. and i.v. inoculation with the H7N7 NL/03 ca virus (Table 3) . Consistent with the absence of the multibasic cleavage site motif in the HA protein, the H7N7 NL/03 ca virus was not lethal for chickens in an intravenous pathotyping test (Table 3) , and virus was not isolated from oropharyngeal or cloacal swabs that were collected on day 3 following i.n. inoculation or from the kidney, heart, brain, and lungs of birds from the i.n. inoculated group that were euthanized at 3 dpi (data not shown). The H7N7 NL/03 ca virus also failed to elicit an antibody response following i.n. inoculation (Table 3 ). The poor replication of the H7N7 NL/03 ca virus in chickens is likely the result of an inability of this ts virus to replicate at the high body temperature of chickens (40°C to 41°C) or the consequence of six internal protein genes from a human influenza virus that fails to replicate efficiently in poultry and suggests that the use of the H7N7 NL/03 ca virus would not pose a threat to the poultry industry.
(ii) Lethality in mice. The H7N7 NL/03 wt and ca viruses were tested for lethality in mice. When administered intranasally, the H7N7 NL/03 wt virus was highly lethal for mice (LD 50 ϭ 10 2 TCID 50 ), while the H7N7 NL/03 ca virus was not lethal for mice even at the highest dose tested (LD 50 Ն 10 6 TCID 50 ).
(iii) Replication of the H7N7 NL/03 ca virus in mice. The level of replication of the H7N7 NL/03 ca virus in mice was determined at 2, 3, and 4 dpi, and the differences were compared with those seen between the AA wt and ca viruses. The level of replication of the H7N7 NL/03 ca virus was significantly lower than that of the H7N7 wt virus in the upper (Fig.  1A) and lower (Fig. 1B) respiratory tracts of mice, and the differences in titer exceeded the difference seen between the titers achieved in mice infected with the AA wt and ca viruses. Although significant levels of NL/03 wt viruses were detected in the brain and spleen (10 3.2 TCID 50 /g and 10 4.5 TCID 50 /g, respectively), the H7N7 NL/03 ca virus was not detected in the brain and spleen (data not shown). Thus, the replication of the H7N7 NL/03 ca virus was highly restricted in mice compared to the H7N7 NL/03 wt virus.
(iv) Replication of the H7N7 NL/03 ca virus in ferrets. The level of replication of the H7N7 NL/03 ca virus was determined in ferrets at 3 dpi, and the difference was compared with that seen between the AA wt and ca viruses. While the H7N7 wt, AA wt, and AA ca viruses replicated to high titers in the upper respiratory tract (10 6.7 TCID 50 /g, 10 4.9 TCID 50 /g, and 10
5.5
TCID 50 /g, respectively), the H7N7 NL/03 ca virus was attenuated and replicated only to a moderate level, between 10 2 and 10 3 TCID 50 /g. The replication of the H7N7 NL/03 ca virus and AA ca virus was not detected in the lower respiratory tract of ferrets (Fig. 2) , while the H7N7 NL/03 wt virus replicated to titers between 10 3 and 10 4 EID 50 /g in the lungs (Fig. 2) . The H7N7 NL/03 ca, AA wt, and AA ca viruses were not detected in the brain and the olfactory bulb, but the H7N7 NL/03 wt virus was detected at moderate and high levels at these sites (10 4.5 TCID 50 /g and 10 6.5 TCID 50 /g, respectively) (Fig. 2) . Thus, the H7N7 NL/03 ca virus was highly restricted in replication in the respiratory tract of ferrets compared to the corresponding wt virus, consistent with the observations of mice, and the virus demonstrated the att phenotype predicted by the genetic modifications engineered into the HA gene segment and the mutations in the internal gene segments that were derived from the AA ca virus.
(v) Replication of the H7N7 NL/03 ca virus in AGMs. Groups of four AGMs were inoculated with the H7N7 NL/03 wt and H7N7 NL/03 ca viruses, and two AGMs were eutha- nized at 2 dpi and 4 dpi, respectively, from each group. Respiratory tissues, including nasal turbinates, trachea, and lungs, were collected, and virus titers in the tissue homogenates were determined ( Table 4 ). The H7N7 NL/03 wt virus replicated well in the upper and lower respiratory tracts. Virus was also detected in respiratory secretions, including nasal and pharyngeal swabs, nasal wash specimens, and tracheal lavage fluid. The virus titer in the tissue samples was slightly higher at 2 dpi than at 4 dpi, but the titers in secretions were variable (Table  4 ). In contrast, virus was detected in respiratory secretions but not in respiratory tissues of animals infected with the H7N7 NL/03 ca virus (Table 4) .
Immunogenicity of the H7N7 NL/03 ca vaccine virus. (i) Immunogenicity in mice.
The immunogenicity of the H7N7 NL/03 ca virus in mice was evaluated following the i.n. administration of 1 or 2 doses of the vaccine virus. A single dose of the H7N7 NL/03 ca vaccine was poorly immunogenic in mice. It induced a low neutralizing antibody response against the homologous virus, with a geometric mean titer (GMT) of 14 and a range of 10 to 32 for individual mice on day 28 postimmunization (Table 5 ). However, the neutralizing antibody response increased significantly after a second dose of the H7N7 NL/03 ca virus, with a GMT of 191 and a range of 143 to 226 for individual mice on day 56 postimmunization ( Table 5 ). The level of cross-neutralizing antibodies against heterologous ck/ BC/04 (H7N3), tk/EG/63 (H7N3), and tk/Italy/99 (H7N1) wt viruses in the sera of mice was determined. Two doses of vaccine induced a robust cross-reactive antibody response against all four H7 viruses (Table 5) .
(ii) Immunogenicity in ferrets. The homologous H7N7 NL/03 wt virus, a heterologous ck/BC/04 (H7N3) wt virus from the North American lineage, and a heterologous tk/EG/63 (H7N3) wt virus from the Eurasian lineage were used for challenge studies in ferrets following 1 or 2 doses of the vaccine. Consistent with findings from the study of mice, after 1 dose of the H7N7 NL/03 ca virus, only a low level of neutralizing antibody was induced against the homologous wt virus (GMT of 12; range, 10 to 13); however, a higher GMT (41; range, 20 to 71) was detected following 2 doses of the vaccine (Table 5 ). The level of cross-neutralizing antibodies against the heterologous ck/BC/04 (H7N3) and tk/EG/63 (H7N3) wt viruses in the sera of ferrets was determined. One and two doses of the H7N7 NL/03 ca virus induced GMTs of 10 and 54, respectively, against the heterologous ck/BC/04 (H7N3) wt virus and GMTs of 15 and 80, respectively, against the heterologous tk/EG/63 (H7N3) wt virus (Table 5) . (ii) Protection from replication of homologous and heterologous H7 challenge viruses in mice. The efficacy of 1 or 2 doses of the H7N7 NL/03 ca virus (10 6 TCID 50 /dose) in preventing the replication of challenge viruses (10 5 TCID 50 /dose) was evaluated on days 2 and 4 following challenge, when all of the challenge viruses were predicted to be present at a high titer in the lungs of mock-immunized animals. The replication of challenge viruses in nasal turbinates, lung, spleen, and brain was evaluated in these mice. Both 1 and 2 doses of vaccination with H7N7 NL/03 ca virus conferred complete protection in the spleen and brain (data not shown). Two doses of the H7N7 NL/03 ca virus vaccine conferred near-complete protection from replication of the homologous NL/03 (H7N7) and heterologous ck/BC/04 (H7N3), tk/EG/63 (H7N3), and tk/Italy/99 (H7N1) wt viruses in the nasal turbinates (Fig. 3A) and lungs (Fig. 3B) , while a significant reduction in titer in the upper respiratory tract (Fig. 3A) without complete protection from pulmonary virus replication was seen following a single dose of the vaccine (Fig. 3B) . Complete protection from replication of H7 wt challenge viruses in the respiratory tract of mice following 2 doses of H7N7 NL/03 ca vaccine was consistent with a high level of neutralizing antibody response against these H7 wt viruses (Table 5) .
(iii) Protection from replication of homologous and heterologous H7 challenge viruses in ferrets. The homologous NL/03 (H7N7) virus and heterologous ck/BC/04 (H7N3) and tk/EG/63 (H7N3) wt viruses from the North American and Eurasian lineages, respectively, were also used for challenge studies in ferrets. Significant reductions (P Ͻ 0.05) in the levels of heterologous challenge virus replication were observed for the upper respiratory tract (Fig. 4A ) when ferrets were challenged 4 weeks after 1 dose of the vaccine. Two doses of the vaccine resulted in a further reduction in the virus titers in the upper respiratory tract (Fig. 4A) . A single dose of the H7N7 NL/03 ca vaccine provided complete protection from replication of the homologous and heterologous H7 wt challenge viruses in the lower respiratory tract (Fig. 4B) . One dose of the vaccine also prevented the spread of the NL/03 (H7N7) wt virus to the brain and significantly reduced (P Ͻ 0.05) the titers of the challenge viruses in the olfactory bulb (data not shown).
(iv) Protection from replication of homologous H7 challenge virus in AGMs. The protective efficacy of the H7N7 NL/03 ca vaccine virus against H7N7 NL/03 wt virus challenge was evaluated in respiratory tissues and secretions harvested 2 days after challenge. Virus was detected in all tissues and secretions from the mock-vaccinated control animal. Virus was not detected in respiratory tissues or secretion samples of the AGM (animal 2) who developed high titers of serum HAI and neutralizing antibodies (Table 6) , whereas virus was detected in respiratory tissues but not in secretions of the two AGMs (animals 3 and 4) who had lower serum neutralizing antibody titers and no detectable HAI antibodies (Table 6) . Thus, the level of protection correlated well with serum neutralizing antibody titers elicited by the vaccine.
Evaluation of the immune mechanism underlying vaccineinduced protection in mice. Because a single dose of the H7N7 NL/03 ca vaccine conferred protection from lethal challenge despite a modest neutralizing antibody response, we determined which effector arm of the immune system protected mice from lethal challenge with H7 wt viruses following 1 or 2 doses of the H7N7 NL/03 ca vaccine.
(i) Evaluation of the role of CD4 ؉ and CD8 ؉ T cells in vaccine efficacy. In order to assess the role of T cells in vaccineinduced protection from homologous and heterologous H7 challenge viruses in mice, we depleted CD8 ϩ and/or CD4 ϩ T cells in mice that received 1 or 2 doses of vaccine by the i.p. injection of anti-CD8 ϩ and/or CD4 ϩ Abs 3 days before and after lethal challenge with H7 wt viruses. We used a protocol for T-cell depletion that was previously shown to deplete these T-cell subsets (12, 15) . Despite the depletion of CD8 ϩ and/or CD4 ϩ T cells, all of the mice immunized with a single dose of the H7N7 NL/03 ca virus survived challenge with all three viruses, including the homologous NL/03 (H7N7) virus and the heterologous ck/BC/04 (H7N3) and tk/EG/63 (H7N3) wt viruses (data not shown). Therefore, we conclude that T lymphocytes are not essential for the protection of vaccinated mice from lethal challenge with H7 wt viruses.
(ii) Evaluation of the role of serum antibody in vaccine efficacy. We generated postvaccination immune serum by administering 1 or 2 doses of the H7N7 NL/03 ca vaccine virus intranasally. We transferred a 1:2 or 1:10 dilution of postvaccination serum to naïve mice via i.p. injection to determine whether antibody alone could protect mice from challenge with the homologous H7N7 NL/03 wt or the heterologous H7N3 ck/BC/04 wt, H7N3 tk/EG/63 wt, or H7N1 tk/Italy/99 wt virus. Nonimmune serum from uninfected mice was administered to control groups. All of the mice that received a 1:2 dilution of the 1-dose postvaccination serum survived challenge with the homologous H7N7 NL/03 wt and heterologous H7N3 ck/BC/04 wt, H7N3 tk/EG/63 wt, and H7N1 tk/Italy/99 wt viruses (Fig. 5) . Mice that received nonimmune serum died between 5 and 6 days postchallenge with the H7N7 NL/03 wt, H7N3 ck/BC/04 wt, or H7N3 tk/EG/63 wt virus (Fig. 5) , as did mice that received a 1:10 dilution of the 1-dose postvaccination serum. Not surprisingly, all of the mice that received a 1:2 or 1:10 dilution of the 2-dose postvaccination serum survived challenge with the homologous H7N7 NL/03 wt or the heterologous H7N3 ck/BC/04 wt, H7N3 tk/EG/63 wt, or H7N1 tk/Italy/99 wt virus (data not shown). These data indicate that the passively transferred serum antibody induced by the H7N7 NL/03 ca vaccine mediates protection from lethality following challenge with H7 wt viruses in mice.
DISCUSSION
The direct transmission of AI H7 subtype viruses from poultry to humans in the course of HPAI outbreaks in poultry in the Netherlands in 2003 and Canada in 2004 has resulted in mild to severe illness in people working closely with infected poultry (17, 26, 35, 40) , including a case of acute fatal respiratory illness in the Netherlands during the HPAI H7N7 virus outbreak in chickens in 2003. As we learned from the H1N1 pandemic of 2009, it is difficult to predict which influenza virus will cross the host species barrier and cause a pandemic. Therefore, it is important to have a library of candidate vaccines for different subtypes that have been evaluated in animal models and in humans. In order to develop vaccines against H7 subtype viruses, we have previously evaluated 10 H7 viruses for their ability to induce high titers of a neutralizing antibody that was cross-reactive within the H7 subtype (22) . Among these 10 viruses, the A/Netherlands/219/03 (H7N7) virus from the Eur- asian lineage induced the most broadly cross-reactive neutralizing antibodies against both Eurasian and North American lineage viruses. We also selected A/ck/BC/CN-6/04 (H7N3) and generated a live attenuated H7N3 BC 04 ca vaccine virus that was evaluated in preclinical trials (23) and phase I clinical trials (39) . In this study, we generated a live attenuated H7N7 NL/03 ca vaccine virus by plasmid-based reverse genetics using the HA and NA genes of the H7N7 NL/03 wt virus and six internal protein genes of a live attenuated influenza A virus vaccine donor strain, the AA ca virus. Three basic amino acid residues at the cleavage site in the HA gene of the H7N7 NL/03 wt virus were genetically modified to remove the multibasic virulence motif, as described previously for H5N1 ca vaccines (37) . Consistent with the absence of the multibasic amino acid motif at the cleavage site in HA, the H7N7 NL/03 ca vaccine virus failed to form plaques in CEF cells in the absence of exogenous trypsin and was not lethal for chickens. The H7N7 NL/03 ca vaccine virus displayed ca, ts, and att phenotypes that are specified by the internal protein genes of the AA ca virus (20, 21) . The safety of the H7N7 NL/03 ca vaccine virus was established in mice, ferrets, and AGMs. The reassortant H7N7 NL/03 ca virus was not lethal for mice. Unlike the wt parent virus, the replication of the H7N7 NL/03 ca vaccine virus was highly restricted in the respiratory tract of mice, and extrapulmonary spread was not observed. The attenuation phenotype was also seen in the ferret and AGM models. In ferrets, the H7N7 NL/03 wt virus replicated to high titers in the upper and lower respiratory tracts, while the H7N7 NL/03 ca virus was attenuated in the nasal turbinates and was undetectable in the lungs, and there was no spread to the brain and spleen. These characteristics of the H7N7 NL/03 ca vaccine virus in ferrets fit the attenuation criteria for the AA ca-based live attenuated influenza virus vaccines that are licensed for human use. In AGMs, the H7N7 NL/03 wt virus replicated to high titers in the nasal turbinates, trachea, and lungs, while the H7N7 NL/03 ca virus was undetectable in all three of these tissues. However, the H7N7 NL/03 ca virus was found at low to moderate titers in respiratory secretions, indicating that the major site of replication for the H7N7 NL/03 ca virus in AGMs may be in the pharynx between the trachea and nasal cavity, and this site should be sampled in future studies. Based on our previous investigation of factors that contributed to the attenuation of an H5N1 ca vaccine (36), we infer that the attenuation of the H7N7 NL/03 ca vaccine virus in mice, ferrets, and AGMs can likely be attributed to the acquisition of the six internal protein gene segments from the AA ca virus and the removal of the multibasic cleavage site in the HA. Live attenuated ca H9N2, H5N1, and H7N3 avian influenza A subtype virus vaccines bearing the six internal protein genes of the AA ca virus have demonstrated similar levels of attenuation in mice and ferrets (10, 23, 37) . Restricted replication in the respiratory tract and the lack of systemic spread in mice and ferrets suggest that the H7N7 NL/03 ca vaccine virus is attenuated and therefore safe for use in humans.
Two doses of the H7N7 NL/03 ca virus induced neutralizing antibodies with broad cross-reactivity in mice and ferrets, but a single dose of the H7N7 NL/03 ca vaccine virus was poorly immunogenic in mice and ferrets. A different phenomenon was observed in the case of the H7N3 ca vaccine, generated against selected based on our evaluation of several H7 viruses (22; our unpublished data). We have previously demonstrated that a single dose of the H5N1 ca or H7N3 ca vaccine provided complete protection from lethality following challenge with homologous and antigenically distinct heterologous H5N1 or H7N3 wt viruses, respectively (23, 37) . In the case of the H7N7 ca vaccine as well, a single dose of the vaccine provided complete protection from lethal challenge with wt H7 viruses in mice. Because this protection was observed in the absence of a robust neutralizing antibody response, we were interested in elucidating the immunological basis for protection from lethal challenge. We found that the presence of T cells at the time of challenge was not essential for protection, while the passive transfer of serum from mice immunized with the H7N7 NL/03 ca virus to naïve mice protected the recipient mice from lethal challenge with H7 wt viruses, demonstrating the importance of antibodies in protection.
Two doses of the vaccine completely protected mice from pulmonary replication of homologous and heterologous viruses from the North American and Eurasian lineages and prevented the dissemination of the challenge viruses to the brain and spleen. This finding is consistent with the robust cross-neutralizing antibody response against these H7 wt viruses after 2 doses of the vaccine. In AGMs, the level of serum neutralizing antibody correlated well with the level of protection, supporting the role of humoral immunity in the protection observed for mice and ferrets. The data from preclinical studies are very valuable for two reasons, first because they provide data that can be used to correlate with immunogenicity data from clinical trials and second because they can provide scientific support for anticipated efficacy in humans, because challenge studies to assess the efficacy of pandemic influenza virus vaccines, such as H7N7 viruses, cannot be conducted in humans. We have previously evaluated the efficacy of H9N2 ca, H5N1 ca, and H7N3 ca vaccines in mice and ferrets. Although a single dose of the H9N2 ca and H7N3 ca vaccines, respectively, protected mice and ferrets from pulmonary replication of the homologous and antigenically heterologous wt challenge viruses (11, 23) , 2 doses of H5N1 ca vaccines were needed to provide complete protection from pulmonary replication of homologous and antigenically distinct heterologous H5N1 wt viruses in mice and in ferrets (37) . Taken together, we see a correlation between neutralizing antibody titers in the serum and protection from pulmonary replication of challenge viruses.
Inactivated vaccines against both lineages of H7 viruses on an A/PR/8/34 (PR/8) (H1N1) backbone have been evaluated in preclinical trials (14, 19, 29) . Formalin-inactivated H7N2/PR8 and H7N7/PR8 whole-virus vaccines with and without aluminum hydroxide adjuvant elicited broadly cross-reactive antibodies against divergent H7 viruses and protected mice against challenge with heterologous H7 wt viruses of both Eurasian and North American lineages (14, 19, 29) . Thus, H7N2, H7N7, H7N1, and H7N3 vaccines have been variably immunogenic yet generally protect experimental animals from challenge with homologous and heterologous H7 viruses. A cell-grown H7N1/PR8 vaccine virus containing the HA and NA genes from HPAI A/ck/Italy/99 (H7N1) virus has been evaluated with humans (13, 42) . This vaccine induced low levels of HAI and neutralizing antibodies, although the addition of an aluminum hydroxide adjuvant enhanced the antibody responses. A live attenuated H7N3 ca vaccine generated in our laboratory was evaluated with healthy adults, and although the vaccine virus was highly restricted in replication, it was highly immunogenic (39) . We selected the NL/03 virus as an additional vaccine target because this virus elicited the most broadly cross-reactive antibody response against a range of antigenically distinct H7 viruses (23) . Based on the promising preclinical data, careful clinical evaluation of the H7N7 NL/03 ca vaccine is warranted. The risk of reassortment of a live attenuated pandemic influenza vaccine virus with a circulating human influenza virus, resulting in a novel subtype of influenza virus that could spread in the human population, is a significant concern. However, we believe that it is important to generate and carefully evaluate candidate live attenuated avian influenza virus vaccines in clinical trials with humans because of their potential advantages over other vaccine approaches (28, 37) , and the risk of reassortment of the live attenuated vaccine virus with human influenza viruses during clinical trials can be minimized by conducting vaccine studies in isolation units when human influenza viruses are not circulating in the community (24, 25, 39) . A live attenuated H7N7 vaccine will be administered to the public only if an influenza pandemic caused by a virus of the H7N7 subtype were imminent, and it will be used only upon the recommendation of public health authorities (28, 37) .
